STOCK TITAN
  1. Home
  2. News
  3. AZN

Astrazeneca Plc - AZN STOCK NEWS

Welcome to our dedicated page for Astrazeneca Plc news (Ticker: AZN), a resource for investors and traders seeking the latest updates and insights on Astrazeneca Plc stock.

AstraZeneca PLC (AZN) is a British-Swedish multinational pharmaceutical and biotechnology company headquartered in Cambridge, England. Formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK, AstraZeneca is known for its extensive research and development in the field of pharmaceuticals and biotechnology.

The company operates globally and generates a significant portion of its revenue from international markets, with the United States accounting for nearly one-third of its sales. AstraZeneca’s product portfolio includes a wide range of branded drugs across several major therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Recent achievements include a global license agreement with Nona Biosciences to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology. The agreement could potentially bring Nona Biosciences up to $575 million upon achieving specified milestones, as well as tiered royalty payments on net sales. AstraZeneca continues to lead in the development of tumor-targeted therapies using cutting-edge technology.

Another noteworthy development is AstraZeneca's collaboration with AbelZeta Pharma to co-develop C-CAR031, a GPC3-targeted CAR-T therapy for treating hepatocellular carcinoma (HCC). The initial clinical results presented at the 2024 ASCO Annual Meeting showed promising safety and efficacy data.

Moreover, AstraZeneca has entered into a significant agreement with Compugen Ltd. to develop rilvegostomig, a PD-1/TIGIT bispecific antibody currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer. This partnership underscores AstraZeneca’s commitment to advancing innovative cancer therapies through strategic collaborations.

With its industry-leading capabilities, AstraZeneca is well-positioned to continue making significant strides in healthcare, providing effective treatments for a variety of diseases and maintaining its reputation as a global leader in pharmaceuticals and biotechnology.

News

Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer

Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's Biologics License Application for datopotamab deruxtecan has been accepted in the U.S. for the treatment of advanced nonsquamous non-small cell lung cancer and HR positive, HER2 negative breast cancer. The BLA is based on positive results from the TROPION-Breast01 phase 3 trial, with a PDUFA date set for January 29, 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.37%
Tags
none
-
News

VOYDEYA™ approved in the US as add-on therapy to ravulizumab or eculizumab for treatment of extravascular hemolysis in adults with the rare disease PNH

Rhea-AI Summary
VOYDEYA (danicopan) has been approved in the US as an add-on therapy for extravascular hemolysis in adults with paroxysmal nocturnal hemoglobinuria. The approval was based on positive results from the pivotal ALPHA Phase III trial, showing efficacy in addressing EVH. VOYDEYA met primary and secondary endpoints, was well-tolerated, and received Breakthrough Therapy designation and PRIME status.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.74%
Tags
none
-
News

ULTOMIRIS® (ravulizumab-cwvz) approved in the US for the treatment of adults with neuromyelitis optica spectrum disorder (NMOSD)

Rhea-AI Summary
ULTOMIRIS, the first long-acting C5 complement inhibitor, receives US FDA approval for treating AQP4 Ab+ NMOSD, showing a 98.6% relapse risk reduction in the CHAMPION-NMOSD trial. NMOSD is a rare autoimmune disease affecting the CNS, with about 6,000 diagnosed cases in the US. The safety profile of ULTOMIRIS remains consistent with previous studies, with COVID-19, headache, back pain, arthralgia, and urinary tract infection being the most common adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.6%
Tags
none
News

AstraZeneca to acquire Fusion to accelerate the development of next-generation radioconjugates to treat cancer

Rhea-AI Summary
AstraZeneca acquires Fusion Pharmaceuticals Inc., a clinical-stage company developing radioconjugates for cancer treatment. The acquisition aims to enhance AstraZeneca's oncology portfolio with a focus on prostate cancer treatment. The deal includes a transaction value of approximately $2.4bn, bringing new expertise and capabilities to AstraZeneca.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.02%
Tags
acquisition
-
News

GRAIL Announces Novel Risk Classification Test to Be Used in Lung Cancer Study

Rhea-AI Summary
GRAIL, in collaboration with AstraZeneca, will test samples from Japanese participants using its risk classification test on the Methylation Platform for lung adenocarcinoma. The study aims to show results within 10 days without tumor tissue, supporting future pharmaceutical trials.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
-
News

AstraZeneca caps patient out-of-pocket costs at $35 per month for its US inhaled respiratory portfolio

Rhea-AI Summary
AstraZeneca expands savings programs for US inhaled respiratory portfolio, offering eligible patients to pay no more than $35 per month for medicines. The company aims to make inhalers more affordable for vulnerable patients with asthma and COPD. Starting June 1, 2024, patients can access this program for various respiratory medicines, including SYMBICORT. AstraZeneca emphasizes its commitment to addressing access and affordability barriers for patients with respiratory diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
none
News

AstraZeneca announces initiation of THARROS – a Phase III clinical trial investigating the potential of BREZTRI to improve cardiopulmonary outcomes in people with COPD

Rhea-AI Summary
AstraZeneca initiates Phase III trial for BREZTRI AEROSPHERE to reduce severe cardiopulmonary outcomes in COPD patients. The ATHLOS trial also begins to compare BGF with other therapies on cardiopulmonary parameters. COPD's impact on global population and the increased risk of cardiopulmonary events are highlighted.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.27%
Tags
clinical trial
-
News

Two Datopotamab Deruxtecan Applications Validated in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer or HR Positive, HER2 Negative Breast Cancer

Rhea-AI Summary
Daiichi Sankyo and AstraZeneca's datopotamab deruxtecan shows significant improvement in progression-free survival in lung and breast cancer. European Medicines Agency validates marketing authorization applications for the drug in two types of cancer, based on phase 3 trial results. The drug aims to replace conventional chemotherapy in the treatment of multiple cancer types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.29%
Tags
none
-
News

MANDARA Phase III data published in New England Journal of Medicine show remission is an achievable goal in eosinophilic granulomatosis with polyangiitis (EGPA) with FASENRA

Rhea-AI Summary
Positive results from the MANDARA Phase III trial for FASENRA in patients with EGPA were published, showing that FASENRA enabled patients to taper off oral corticosteroids while preventing relapses. The trial demonstrated that more than half of patients achieved remission with eosinophil-targeting biologic therapies, with benralizumab meeting the primary endpoint and showing non-inferior rates of remission compared to mepolizumab.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
clinical trial
News

TAGRISSO® (osimertinib) demonstrated overwhelming efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Phase III trial

Rhea-AI Summary
AstraZeneca's TAGRISSO shows significant progression-free survival benefit in Stage III lung cancer patients with EGFR mutations, positioning it as a potential targeted treatment option. The LAURA Phase III trial results indicate a favorable trend in overall survival, with TAGRISSO demonstrating impactful clinical benefit in a potentially curative setting. Safety and tolerability profiles remain consistent, with ongoing investigations in neoadjuvant and adjuvant settings.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial

FAQ

What is the current stock price of Astrazeneca Plc (AZN)?

The current stock price of Astrazeneca Plc (AZN) is $74.22 as of February 21, 2025.

What is the market cap of Astrazeneca Plc (AZN)?

The market cap of Astrazeneca Plc (AZN) is approximately 231.2B.

What is AstraZeneca PLC?

AstraZeneca PLC is a British-Swedish multinational pharmaceutical and biotechnology company formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK. It is headquartered in Cambridge, England.

What therapeutic areas does AstraZeneca focus on?

AstraZeneca’s product portfolio includes drugs across several therapeutic areas such as gastrointestinal, diabetes, cardiovascular, respiratory, oncology, immunology, and rare diseases.

Where does AstraZeneca generate most of its revenue?

A significant portion of AstraZeneca’s revenue comes from international markets, with the United States accounting for nearly one-third of its sales.

What is the recent collaboration between AstraZeneca and Nona Biosciences about?

AstraZeneca and Nona Biosciences have entered into a global license agreement to develop preclinical monoclonal antibodies aimed at creating targeted therapies in oncology.

What is C-CAR031?

C-CAR031 is a GPC3-targeted CAR-T therapy developed by AstraZeneca and AbelZeta Pharma for treating hepatocellular carcinoma (HCC). Initial clinical results have shown promising safety and efficacy data.

What is rilvegostomig?

Rilvegostomig is a PD-1/TIGIT bispecific antibody developed by AstraZeneca in collaboration with Compugen Ltd. It is currently in Phase 3 trials for non-small cell lung cancer and biliary tract cancer.

What are some of AstraZeneca’s key recent achievements?

Recent achievements include a global license agreement with Nona Biosciences for oncology therapies, collaboration with AbelZeta Pharma on C-CAR031, and partnership with Compugen Ltd. for developing rilvegostomig.

Where is AstraZeneca headquartered?

AstraZeneca is headquartered at the Cambridge Biomedical Campus in Cambridge, England.

When was AstraZeneca formed?

AstraZeneca was formed in 1999 through the merger of Astra AB of Sweden and Zeneca Group PLC of the UK.

What is the focus of AstraZeneca’s research and development?

AstraZeneca focuses on research and development in pharmaceuticals and biotechnology, particularly in creating treatments for various major therapeutic areas including cancer, respiratory diseases, cardiovascular conditions, and more.
Stock AZN logo
Astrazeneca Plc

Nasdaq:AZN

AZN Rankings

#rank Ranked by Market Cap
#rank Ranked by Dividends

AZN Stock Data

231.16B
3.10B
0.01%
16.77%
0.49%
Drug Manufacturers - General
Healthcare
Link
United Kingdom
Cambridge